Extended Data Fig. 1: AR protein levels are prognostic in ER-positive breast cancer.
From: The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Immunogenic AR protein levels predict breast cancer-specific survival in the Nottingham Tenovus Primary Breast Cancer Series14. Kaplan–Meier plots depicting the association between immunogenic AR positivity (dichotomized by high ≥ 78% and low < 78% nuclear staining based on an optimal cut-point criterion8) and breast cancer-specific survival. a, All cases; b, ER-positive cases (defined by immunogenic ER positivity of >1% as per current ASCO guidelines); c, High-risk (defined by Nottingham Prognostic Index ≥ 3.4) ER-positive cases treated with adjuvant endocrine therapy (Tamoxifen; Tam); d, ER-positive cases not treated with adjuvant Tamoxifen. Survival probabilities were estimated using a univariate Cox proportional hazards model. Differences between survival rates were tested for significance using the log-rank test. Hazard ratios (HR), 95% confidence intervals (95% CI), and p values are provided within each graph. All tests were two-sided.
